Cempra Holdings (CEMP) Tops Q2 EPS by 7c

Cempra Holdings (NASDAQ: CEMP) reported Q2 EPS of ($0.49), $0.07 better than the analyst estimate of ($0.56).

Financial Guidance

Cempra expects its research and development expense to continue at least at current levels for the next several quarters due to the concurrent running of its two Phase 3 programs for solithromycin as well as its other programs. The company's cash and equivalents are expected to be sufficient to fund current operations through 2015, assuming continued timely receipts under the BARDA contract, receipt of expected milestone payments from Toyama and the amended payment terms of Cempra's venture debt facility. This projection does not include any funds from future financings or partnerships beyond the Toyama and BARDA relationships.

For earnings history and earnings-related data on Cempra Holdings (CEMP) click here.

You May Also Be Interested In

• Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
• Orange shares down despite reporting in-line core operating profit in Q1
• United Microelectronics (UMC) Reports In-Line Q1 EPS, provides outlook